Logo
  • Home
  • AI Agent
  • Annotations
  • Watchlists
  • Files
  • Pricing and plans
  • BlogAboutContact us
    APIMCP
    Terms of servicePrivacy policy

  • Get the full experience

    We save the real magic for signed-in users.

Logo
TWST US​

Twist Bioscience Corp(TWST US)

$139.92+4.453.28%Ext:$137.37-2.551.82%(Market Closed · 00:00:02 UTC)

Overview

ProfileEntity Structure

Documents

SEC Filings

Financials & Metrics

FinancialsChartingShort InterestEmployees

Twist Bioscience Corp — Company Profile

Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.

Sector
Materials
Industry
Paper & Forest Products
Exchange
UQ
CEO
Emily Marine Leproust
Headquarters
South San Francisco, CA, US
IPO Date
Oct 31, 2018
Employees
979
Website
www.twistbioscience.com

Key Metrics

Price
$188.67
Market Cap
$11.75B
Revenue (TTM)
$110.72M
Net Income (TTM)
$-44021000.00
EPS (TTM)
-0.71
P/E (TTM)
-144.55
P/B (TTM)
25.82
Dividend Yield
0.00%
ROE (TTM)
-9.67%
ROA (TTM)
-6.51%
Operating Margin
-41.42%
Beta
1.77

Dividends

Last Dividend
$0.00
Last Yield
0.00%

Summary

Twist Bioscience Corporation operates as a leading synthetic biology firm, specializing in the production and sale of products developed from synthesized DNA. The company utilizes a unique DNA synthesis platform that facilitates the creation of artificial DNA by "writing" it directly onto silicon chips. Its extensive product catalog encompasses custom synthetic genes, specialized tools designed for sample preparation, comprehensive antibody libraries essential for pharmaceutical research and development, and advanced applications leveraging DNA for digital data storage. Twist Bioscience has established strategic collaborations with several organizations, including Victorian Clinical Genetic Services, Vivlion GmbH, Kyowa Kirin Pharmaceutical Research, Inc., deepCDR Biologics AG, and Centogene N.V., with the shared goal of innovating advanced sequencing technologies. Furthermore, the company engages in a research alliance with Boehringer Ingelheim International GmbH, where it applies its exclusive antibody libraries to identify and develop therapeutic antibodies against a multitude of targets. The corporation was founded in 2013 and is headquartered in South San Francisco, California.

Website
www.twistbioscience.com
Location
South San Francisco, CA, US
Phone800 719 0671
Employees979
CEOEmily Marine Leproust
Sector
Materials
Industry
Paper & Forest Products
IPO DateOct 31, 2018

Ask AI

Company overview
Business model, segments, and competition.
Peer comparison
Metrics vs closest competitors.
Guidance & outlook
Forward guidance and assumptions.
Bull vs bear case
Upside drivers and key risks.
Valuation snapshot
Multiples vs history and peers.
Competitive moat
Defensibility and market position.
Management track record
Leadership and capital allocation history.

Latest Documents

SEC Filings(1.6K)

Expand
  • 144Finn Patrick John23 Oct
  • 4Laponis Adam13 Oct
  • 144Laponis Adam9 Oct
  • 4Leproust Emily M.7 Oct
  • 144Leproust Emily M.5 Oct
  • 4Laponis Adam5 Oct
  • 4Green Paula5 Oct
  • 4Finn Patrick John5 Oct
  • 4Leproust Emily M.5 Oct
  • 4Cho Dennis5 Oct
  • 4WERNER ROBERT F.5 Oct
  • 144Green Paula2 Oct
  • 144WERNER ROBERT F.2 Oct
  • 144Cho Dennis2 Oct
  • 144Leproust Emily M.2 Oct
  • 144Laponis Adam2 Oct
  • 144Finn Patrick John2 Oct
  • 144Leproust Emily M.1 Oct
  • 4Leproust Emily M.25 Sep
  • 144Leproust Emily M.24 Sep

News

  • Alger Small Cap Focus Fund Q3 2026 Portfolio Update23 Oct
  • Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy?22 Oct
  • Twist Bioscience (NASDAQ:TWST) Shares Down 7.4% – Here’s Why18 Oct
  • Polen 5Perspectives Small-Mid Growth Q3 2026 Portfolio Update15 Oct
  • How to Invest in AI Drug Discovery14 Oct
  • These 3 Stocks Are Crushing the "Magnificent Seven" This Year -- Are They Still Buys?12 Oct
  • Head to Head Survey: Quantum-Si (NASDAQ:QSI) versus Twist Bioscience (NASDAQ:TWST)8 Oct
  • Twist Bioscience (NASDAQ:TWST) Stock Falls 9.7% Following Insider Selling6 Oct
  • The Top HealthTech Questions Landing on Our Desks30 Sep
  • Twist Bioscience Stock Hits New High, Then Retreats: What's Happening?25 Sep
  • 3 Analysts, 3 Trades to Make Today22 Sep
  • Why Twist Bioscience Stock Skyrocketed This Week18 Sep
  • Beyond Hype: Twist Bioscience Secures Data Pipeline Role In Eli Lilly TuneLab Ecosystem16 Sep
  • Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery16 Sep
  • Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery16 Sep
  • AI & Robotics in 2026: 16 Recent Developments for Investors9 Sep
  • Twist Bioscience to Present at Baird 2026 Global Healthcare Conference9 Sep
  • Brandywine Managers LLC Invests $2.16 Million in Twist Bioscience Corporation $TWST25 Aug
  • 90,053 Shares in Twist Bioscience Corporation $TWST Acquired by Deutsche Bank AG24 Aug
  • Twist Biosciences: AI-Driven Rally Or Short Squeeze? I'm Neutral (For Now)20 Aug

Mentions in Filings

  • … 1 +165% $2.8B Strive ASST 2 +151% $697M OmniAb OABI 3 +146% $448M Capricor Therapeutics CAPR 4 +138% $383M Arcturus Therapeutics ARCT 5 +128% $6.2B Kodiak Sciences KOD 6 +115% $667M Chaince Digital CD 7 +111% $10.0B <strong>Twist Bioscience</strong> TWST 8 +105% $2.0B Schrödinger SDGR 9 +104% $6.0B GRAIL GRAL 10 Price return, Jul 31 to Sept 30, 2026 (August and September), about 2,000 companies Deep daily liquidity in both ASST and SATA Average daily dollar vol …
    Strive, Inc.Twist Bioscience Corp·FWP - Free writing prospectus·Q4 26·13 Oct
  • … , sustainability and governance committee of Deckers Outdoor Corporation (NYSE), a footwear, apparel and accessories designer and distributor; on the board, audit committee, and nominating and governance committee of <strong>Twist Bioscience</strong> (NASDAQ), which manufactures synthetic DNA; and on the board and nominating and corporate governance committee of GCT Semiconductors (NYSE), a fabless designer and supplier of advanced 4G LTE, IoT and 5G semiconducto …
    SYNAPTICS IncTwist Bioscience Corp·DEF 14A - Definitive proxy statement·Q1 27·15 Sep
  • … recovery method, the Company does not expect to recognize any income related to royalties received until the purchase price has been fully collected. No allowance for credit losses was recorded as of June 30, 2026. <strong>Twist Bioscience</strong> Royalty Purchase Agreement In October 2024, the Company entered into the Twist RPA. Under the terms of the Twist RPA, the Company acquired 50% of certain contingent payments (including royalties, milestone payments, …
    LIGAND PHARMACEUTICALS INCTwist Bioscience Corp·EX-99.2 - 8-K/A - Financial Statements and Exhibits·Q3 26·2 Sep
  • … 2025, Mr. Kelly was Finance Director at Medac Pharma, a UK-based pharmaceutical sales company. From 2022 to 2024, he was the Head of Glasgow Finance at Chubb Insurance. From 2021 to 2022, he was a Finance Director at <strong>Twist Bioscience</strong> Corp., a manufacturer of synthetic DNA for various industries, from life sciences research to data storage technology. He was also a Senior Finance Director and European Controller at Charles River Laboratories, a co …
    Coda Octopus Group, Inc.Twist Bioscience Corp·DEF 14A - Definitive proxy statement·Q4 26·17 Aug
  • #\*TransMedics Group, Inc. 8,957 1,200,014 \* Treace Medical Concepts, Inc. 1,785 4,141 \* Trevi Therapeutics, Inc. 2,157 22,584 \* TruBridge , Inc. 236 4,567 \*Twist Bioscience Corp. 13,996 574,816
    Dimensional ETF TrustTwist Bioscience Corp·NPORT-EX - NT NPORT-P - Notification of late filing (portfolio holdings)·Q1 26·13 Aug
  • … 2025, Mr. Kelly was Finance Director at Medac Pharma, a UK-based pharmaceutical sales company. From 2022 to 2024, he was the Head of Glasgow Finance at Chubb Insurance. From 2021 to 2022, he was a Finance Director at <strong>Twist Bioscience</strong> Corp., a manufacturer of synthetic DNA for various industries, from life sciences research to data storage technology. He was also a Senior Finance Director and European Controller at Charles River Laboratories, a co …
    Coda Octopus Group, Inc.Twist Bioscience Corp·PRE 14A - Preliminary proxy statement·Q4 26·6 Aug

Key Stats

Trading

Px/Chg 1D$188.67 / +0.33%
Avg Volume1.52M
Beta1.77
Mkt Cap11.75B
FD Mkt Cap8.55B

Float

Shrs Out/Float62.27M / 59.69M
Short Float0.23%
Days to Cover5.51
Stock Repurchased$8.00K

Current Valuation

EV11.72B
EV/EBITDA-208.05
EV/Sales28.63
P/B25.82
P/S28.69
FCF Yield-0.22%
ROE-9.67%
ROA-6.51%
Current Ratio2.70

Estimates

P/E-144.55
Est P/EN/A
Est EPSN/A
Est PEGN/A

Valuation

Metric5Yr AvgAug '23Feb '24Jan '25Jan '26Oct '26
PRICE-BASED RATIOS
Price / Earnings-77.56-5.68-9.25-14.56-91.44-266.89
Price / Sales30.946.087.729.7125.06106.12
Price / Book Value8.421.573.036.435.2525.82
Price / Free Cash Flow-124.56-5.47-11.11-43.93-102.37-459.90
ENTERPRISE VALUE METRICS
Enterprise Value3,941.8954.51,699.62,897.02,435.911,721.9
Enterprise Value / Sales30.274.696.939.2624.60105.87
Enterprise Value / EBITDA-91.51-4.51-9.76-16.39-116.67-310.23
Enterprise Value / EBIT-76.72-4.18-8.35-13.92-90.61-266.54

Financials

Full Financials
Millions USD5Yr CAGR (%)Sep '21Sep '22Sep '23Sep '24Sep '25
INCOME STATEMENT
Revenue29.9%132.3203.6245.1313.0376.6
Gross Income38.6%51.784.289.7133.3191.0
EBITDA-22.4%-143.9-211.7-174.2-176.7-52.1
EBIT-15.9%-153.7-228.2-203.5-208.1-77.0
Net Income-15.5%-152.1-217.9-204.6-208.7-77.7
EPS (Diluted)-19.8%-3.15-4.04-3.60-3.60-1.30
BALANCE SHEET
Cash & ST Inv-16.5%477.9505.0336.4276.4232.4
Total Assets-2.2%702.1961.4776.4614.3641.9
Total Liabilities8.6%121.3172.0153.0141.6168.9
Total Shareholder Equity-5%580.8789.4623.4472.7473.0
CASH FLOW
Net Operating Cash Flow-19.3%-112.2-124.4-142.5-64.1-47.6
Cap Ex86%-27.1-101.9-27.8-5.1-28.0
Free Cash Flow-14.2%-139.3-226.2-170.3-69.2-75.6

Enterprise Value Bridge

Millions USD23 Oct '26
Price (As of 23 Oct '26)138.50
Basic Shares62.27
Market Cap8,624.6
Diluted Shares61.70
Fully Diluted Shares Outstanding61.70
Fully Diluted Market Cap8,545.7
+Consolidated Debt95.8
−In-the-Money Convertible Debt—
+Capital Leases95.8
+Operating Leases—
−Cash & Equivalents-122.7
−Short-term Investments-49.0
+Total Preferred-
−In-the-Money Convertible Preferred—
−Investments in Unconsolidated Subs—
+Non-Controlling Interest-
+Pension Liabilities—
Enterprise Value8,597.7

Segment data

Revenue

by Products and services

  • Ngs Tools55%
  • Synthetic Genes30%
  • Antibody Discovery6%
  • Oligo Pools5%
  • Dna And Biopharma Libraries3%

Revenue

by Geography

  • Americas60%
  • Emea33%
  • Asia Pacific7%

Related companies

Amgen Inc

AMGN US

Gilead Sciences, Inc.

GILD US

Intuitive Surgical Inc

ISRG US

Moderna, Inc.

MRNA US

Argenx Se

ARGX US

Edwards Lifesciences Corporation

EW US

Revolution Medicines, Inc.

RVMD US

Biogen Inc.

BIIB US

BioNTech SE

BNTX US

STERIS plc

STE US

Nordson Corp

NDSN US

Tyson Foods, Inc.

TSN US